PMID- 33458868
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1472-8206 (Electronic)
IS  - 0767-3981 (Linking)
VI  - 35
IP  - 3
DP  - 2021 Jun
TI  - The clinical meaning of levodopa equivalent daily dose in Parkinson's disease.
PG  - 620-630
LID - 10.1111/fcp.12646 [doi]
AB  - Levodopa (L-dopa) remains the basis of pharmacological treatment of Parkinson's 
      disease (PD). However, L-dopa therapy is associated with the development of 
      complications and presents major challenges in the long-term treatment. Thus, 
      other medications may be suggested to delay and/or reduce the doses of L-dopa in 
      order to prevent complications. The interpretation of treatment evolution 
      reported in clinical trials on PD may be tricky, especially due to some 
      variability in medications and dose regimens. Some authors have suggested a 
      conversion factor to generate a total L-dopa equivalent daily dose (LEDD), 
      calculated as a sum of each parkinsonian medication. Therefore, LEDD provides an 
      artificial summary of the total daily medication a patient is receiving, and to 
      date, there is no report focusing on the clinical interpretation of this 
      parameter. Thus, based on a 3-year, multi-center retrospective study assessing 
      the impact of second-line therapy initiation on LEDD in PD patients, the aim of 
      our article was to discuss LEDD as a quantitative outcome to estimate the impact 
      of second-line therapies on medication regimens; and in the second part of the 
      discussion, to provide a narrative review of the clinical outcomes associated 
      with LEDD in the literature.
CI  - (c) 2021 Societe Francaise de Pharmacologie et de Therapeutique.
FAU - Julien, Charlotte
AU  - Julien C
AD  - Assistance Publique Hopitaux de Marseille, Hopital de la Timone, Service de 
      Pharmacie, Marseille, France.
FAU - Hache, Guillaume
AU  - Hache G
AUID- ORCID: 0000-0002-6474-8101
AD  - Assistance Publique Hopitaux de Marseille, Hopital de la Timone, Service de 
      Pharmacie, Marseille, France.
FAU - Dulac, Morgane
AU  - Dulac M
AD  - Assistance Publique Hopitaux de Marseille, Hopital de la Timone, Service de 
      Pharmacie, Marseille, France.
FAU - Dubrou, Clea
AU  - Dubrou C
AD  - Assistance Publique Hopitaux de Marseille, Hopital de la Timone, Service de 
      Pharmacie, Marseille, France.
FAU - Castelnovo, Giovanni
AU  - Castelnovo G
AD  - Centre Hospitalier Universitaire de Nimes, Service de Neurologie, Nimes, France.
FAU - Giordana, Caroline
AU  - Giordana C
AD  - Centre Hospitalier Universitaire de Nice, Hopital Pasteur 2, Service de 
      Neurologie, Nice, France.
FAU - Azulay, Jean-Philippe
AU  - Azulay JP
AD  - Assistance Publique Hopitaux de Marseille, Hopital de la Timone, Service de 
      Neurologie pathologies du mouvement, Centre expert et de coordination 
      interregional pour la maladie de Parkinson, Marseille, France.
FAU - Fluchere, Frederique
AU  - Fluchere F
AD  - Assistance Publique Hopitaux de Marseille, Hopital de la Timone, Service de 
      Neurologie pathologies du mouvement, Centre expert et de coordination 
      interregional pour la maladie de Parkinson, Marseille, France.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Systematic Review
DEP - 20210223
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Neuroprotective Agents)
RN  - 46627O600J (Levodopa)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antiparkinson Agents/*administration & dosage/adverse effects
MH  - Clinical Trials as Topic
MH  - *Drug Dosage Calculations
MH  - Female
MH  - Humans
MH  - Levodopa/*administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Neuroprotective Agents/*administration & dosage/adverse effects
MH  - Parkinson Disease/*drug therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - levodopa equivalent daily dose
OT  - parkinson disease
EDAT- 2021/01/19 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/01/18 05:38
PHST- 2020/12/14 00:00 [revised]
PHST- 2020/07/26 00:00 [received]
PHST- 2021/01/12 00:00 [accepted]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/01/18 05:38 [entrez]
AID - 10.1111/fcp.12646 [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2021 Jun;35(3):620-630. doi: 10.1111/fcp.12646. Epub 2021 
      Feb 23.